AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02831842 — intervention group
Intervention type: DRUG
Intervention: Anti-EGFR-Containing Regimen
Description: Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
Study NCT02831842 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab-containing regimen
Description: Study protocol does not specify any particular bevacizumab containing regimen. The data will be collected retrospectively.
Study NCT02831842 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
Study NCT01678716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHC + BCC
Description: This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
Study NCT02796131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791
Study NCT01678716 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient powders
Description: In this intervention arm, frontline health workers will visit households and promote and sell micronutrient powders to them. The micronutrient powder is sold by the brand name Pushtikona in Bangladesh and contains 15 micronutrients including iron, zinc, vitamin A, vitamin C, and others.
Study NCT01678716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mass media
Description: A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
Study NCT01678716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mass media
Description: A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
Study NCT03333330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visipaque 320 and SonoVue
Description: Intervention is related to the administration of contrast agents:~Iodixanol, 320 mg of iodine per millilitre, Visipaque 320 (GE Healthcare, Milwaukee, WI, USA) for contrast-enahnced CTA, Sodium hexafluoride (SonoVue, Bracco Imaging, Milan, Italy) for CEUS
Study NCT04529421 — intervention group
Intervention type: BEHAVIORAL
Intervention: Online instruction
Description: For some courses and groups of students, instruction is primarily offered digitally, so that the students can participate from outside campus.
Study NCT04529421 — intervention group
Intervention type: BEHAVIORAL
Intervention: In-person instruction
Description: For some courses and groups of students, instruction is primarily offered in-person, on campus (or elsewhere).
Study NCT02796131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT04327440 — intervention group
Intervention type: OTHER
Intervention: PBO bed nets
Description: PBO nets: The PBO nets represent a new formulation of insecticide-treated bed nets with a chemical synergist, piperonyl butoxide (PBO), designed to enhance the insecticidal effect of pyrethroids. They seem to be helpful in areas like Malawi where insecticide-resistance is increasing. PBO inhibits the enzyme that detoxifies the pyrethroid, allowing the pyrethroid to act on the mosquito. The impact of PBO net use was also detectable in key entomological measures including Anopheles density, sporozoite rate and entomological inoculation rates. Following these promising preliminary results in Tanzania, Malawi's National Malaria Control Program (NMCP) is piloting the use of PBO-nets iin one of our two study sites, presenting us with the opportunity to study the effectiveness of these nets in the context of real-world program setting
Study NCT02901613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy
Study NCT00653965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT00653965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study NCT02621034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: K-file hand instrumentation
Study NCT02621034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciproc
Description: reciprocating rotary instrument
Study NCT02621034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One shape
Description: full rotation protocol
Study NCT02860065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPC-201
Description: solifenacin and donepezil
Study NCT02860065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Description: measure activity of cerebral acetylcholinesterase
Study NCT02091141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Study NCT02091141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Study NCT02091141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Study NCT02091141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Study NCT02091141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Study NCT02091141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Study NCT02091141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Study NCT02091141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Study NCT01421342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Switching: Bupropion-SR
Description: Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
Study NCT01421342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmenting: Antidepressant + Bupropion-SR
Description: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.~And~Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
Study NCT01421342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmenting: Antidepressant + Aripiprazole
Description: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.~And~Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
Study NCT02150967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398 (infigratinib)
Description: Capsule for oral use
Study NCT04498572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: dry needling for Gluteus Medius muscle in combination with exercises
Study NCT04498572 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham dry needling
Description: sham dry needling for Gluteus Medius muscle in combination with exercises
Study NCT03039933 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fear of Hypoglycemia
Description: Participants will receive exposure and response prevention and/or hypoglycemia awareness training.
Study NCT01904721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Solution 1
Description: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
Study NCT01904721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Solution 2
Description: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
Study NCT03039933 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual
Description: Treatment As Usual
Study NCT02190747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.
Study NCT02190747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00641524 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phlebotomy
Description: Phlebotomy involves the removal of blood (approximately 500mL) each week until body iron levels reach the low-normal level
Study NCT02076659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F8IL10
Description: Weekly administration of F8IL10 (from 6 to 600 μg/kg), starting from 6 μg/kg cohort 1. The cohort 10 represents the last dose-level of the study.~F8IL10 will be administered as subcutaneous (s.c.) injections. Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent.
Study NCT02800486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial Cetuximab
Study NCT02800486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial Mannitol
Study NCT02800486 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated re-irradiation
Study NCT02937532 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: GHE + TOBT training
Description: All subjects will receive 45 minutes of GHE, followed by 45 minutes of TOBT program twice a week for 8 weeks.
Study NCT01904721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Vehicle
Description: Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
Study NCT01904721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bimatoprost Vehicle
Description: Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
Study NCT03332121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B001
Description: 4 times intravenous injection totally,dosing at Day1,Day35,Day56,Day77
Study NCT00532844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin Dihydrochloride
Description: Sapropterin Dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
Study NCT00532844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin Dihydrochloride and Vitamin C
Description: Sapropterin Dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
Study NCT01382771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular corticosteroid injection
Description: Intra-articular injection of 0.5 cc triamcinolone acetonide (40 mg/cc) within each joint
Study NCT01382771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intra-articular saline injection
Description: Intra-articular injection of 0.5 cc normal saline in each joint
Study NCT05908838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified Banxia Xiexin Decoction
Description: The treatment group#Modified Banxia Xiexin Decoction group#was given Modified Banxia Xiexin Decoction, 2 bags each time, 2 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and S-1 monotherapy regimen.
Study NCT05908838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: combination chemotherapy with Placebo granules
Description: combination chemotherapy with Placebo granules
Study NCT03734822 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: End tidal CO2 (EtCO2)
Description: End tidal CO2 (EtCO2) is monitored through the endotracheal tube during general anesthesia.
Study NCT03734822 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous CO2 (TCO2)
Description: Continuous and noninvasive real-time monitoring of transcutaneous CO2.
Study NCT03734822 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Capillary CO2 (CapCO2)
Description: Capillary CO2 collected by finger stick and run on the i-STAT handheld blood analyzer.
Study NCT03734822 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Arterial blood gas (ABG)
Description: Arterial blood gas collected from the radial artery and run on the i-STAT handheld blood analyzer.
Study NCT03822078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT03822078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection
Study NCT02519257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAD
Description: Patients with CAD diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
Study NCT02519257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VHD
Description: Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
Study NCT04201093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon
Description: Participants will be randomized to receive tavapadon 5 mg QD or 15 mg QD tablet once daily orally for 27 weeks.
Study NCT04201093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
Study NCT03733470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil study group
Description: One dose of 20 mg Sildenafil will be given one hour before CT imaging.
Study NCT02076659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered at a fixed dose of 10-15 mg on Day 1, orally (p.o.), subcutaneously (s.c.) or intramuscularly (i.m.).~Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent.
Study NCT01638026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIPTORELIN ACETATE, hCG
Description: In the study group women will receive GnRH agonist (decapeptyl 0.2 mg) for oocyte maturation, followed by ovum pick-up which will be performed 35 hours later. Embryo transfer will be performed 48-72 hours after ovum pick-up. Luteal support will include HCG 1500 IU.
Study NCT02378896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Computer Program
Description: Training with a personalized computerized inhibitory training program
Study NCT02378896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
Study NCT02752503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Study NCT02094807 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NSAID
Description: Will be used if other drugs are not tolerated.
Study NCT02094807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: Will be used if other drugs are not tolerated.
Study NCT02094807 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: thoracic epidural anesthesia
Description: Continous epidural anesthesia will be introduced by specialists in Anesthesia and Intensive care.
Study NCT02094807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural anesthesia
Description: Continous epidural anesthesia will be introduced by specialists in Anesthesia and Intensive care.
Study NCT02094807 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: opioids
Description: During firs 24 hours i.v will be used. Then slow releas tabletts will be preferred.
Study NCT02094807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: opioids
Description: During firs 24 hours i.v will be used. Then slow releas tabletts will be preferred.
Study NCT02094807 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: paracetamol
Description: 100mg x 4 i.v. during the first 24 hours. Then orally 100mg x 4.
Study NCT02094807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: 100mg x 4 i.v. during the first 24 hours. Then orally 100mg x 4.
Study NCT02094807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operative fixation of rib fractures
Description: Fractures will be stabilized on the outside of of the ribs.
Study NCT04083664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NGAL and Hepcidin
Description: Both NGAL and hepcidin are elevated inchronic kidney disease,not only through iron metabolism, but both are also associated with inflammationand may be related to anemia
Study NCT04580316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental active presence
Description: The parents were allowed to stand close to their children, do handholding, eye contacting and help in explaining the dentist's instructions.
Study NCT04580316 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Parent passive presence
Description: Parents were instructed to sit silently in the dental clinic behind the patient with no eye contact, and without a spoken word only to reassure their children
Study NCT04659018 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood collection
Description: A 5ml blood sample will be taken in a dry tube when the venous line necessary for the general anaesthesia for the colonoscopy is placed.
Study NCT03081611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ram cannula
Description: Ventilatory support for preterm infants using Ram cannula
Study NCT03081611 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short nasal prongs
Description: Ventilatory support for preterm infants using short nasal prongs
Study NCT02937532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT + TOBT training
Description: All subjects will receive 45 minutes of CBT, followed by 45 minutes of TOBT program twice a week for 8 weeks.
Study NCT04629768 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PuraStat
Description: Purastat is applied to the EMR defect
Study NCT04124666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocytes
Description: Granulocytes cross-matched for ABO-Rh and CMV; bioactivity of anti-cancer ability meets the criteria.
Study NCT03876977 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic laparoscopic decompression of pudendal nerve entrapment
Description: Robotic laparoscopic decompression of pudendal nerve entrapment.~Transperitoneal Laparoscopic Robotic assistance
Study NCT04842136 — intervention group
Intervention type: OTHER
Intervention: Scales and indexes
Description: Patients with TMD regardless of diagnosis with sleep bruxism were assessed with the Jaw Function Limitations Scale (JFLS), Neck Disability Index (NDI), Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and Headache Impact Test-6 (HIT-6) scales.
Study NCT03055442 — intervention group
Intervention type: OTHER
Intervention: Dosage of myo-inositol
Description: Quantitative analysis of myo-inositol was performed by gas chromatography-mass spectrometry (GC-MS)